Escitalopram and Depression in Elderly Alzheimer's Patients

This study has been terminated.

( Dr. Rabheru left VCH last year and the study was cancelled according to his research coordinator. )

First Received on June 18, 2007. Last Updated on June 2, 2011 History of Changes

Sponsor:	University of British Columbia
Information provided by:	University of British Columbia
ClinicalTrials.gov Identifier:	NCT00488670

Purpose

To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

Condition	Intervention	Phase
Depressive Disorder	Drug: Escitalopram	Phase III

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease Dementia Depression

Drug Information available for: Benzetimide Dexetimide Citalopram hydrobromide Citalopram Escitalopram Escitalopram oxalate

U.S. FDA Resources

Further study details as provided by University of British Columbia:

Primary Outcome Measures:

Change in Cornell Scale for Depression in Dementia (CSDD) from baseline. [ Time Frame: Unspecified ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study [ Time Frame: Unspecified ] [ Designated as safety issue: No ]

Estimated Enrollment:	50
Study Start Date:	December 2010
Study Completion Date:	June 2011
Primary Completion Date:	June 2011 (Final data collection date for primary outcome measure)

Intervention Details:

See Detailed Description.

Detailed Description:

This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

> 50 years
Male & female
Alzheimer's disease
Depressive episode

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00488670

Locations

Canada, British Columbia
Vancouver General Hospital
Vancouver, British Columbia, Canada
Mt. St. Joseph's Hospital
Vancouver, British Columbia, Canada

Sponsors and Collaborators

University of British Columbia

Investigators

Principal Investigator:

Kiran Rabheru, MD

University of British Columbia

More Information

No publications provided

Responsible Party:	Dr. Kiran Rabheru, University of British Columbia
ClinicalTrials.gov Identifier:	NCT00488670 History of Changes
Other Study ID Numbers:	H07-00050
Study First Received:	June 18, 2007
Last Updated:	June 2, 2011
Health Authority:	Canada: Health Canada

Keywords provided by University of British Columbia:

Alzheimer's disease
elderly
open-label
escitalopram

Additional relevant MeSH terms:

Alzheimer Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Mood Disorders
Behavioral Symptoms
Dexetimide

Citalopram
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on February 09, 2012